ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study

Kuemmel S, Fasching P, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, Cortes J, Dent R, O'Shaughnessy J, Pusztai L, Foukakis T, Park YH, Hui R, Cardoso F, Denkert C, Jia L, Pan W, Karantza V, McArthur H (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Book Volume: 33

Pages Range: 5632-5634

Journal Issue: 6

DOI: 10.1245/s10434-026-19310-z

Authors with CRIS profile

Involved external institutions

Queen Mary University of London United Kingdom (GB) Klinikum der Universität München (LMU Klinikum) Germany (DE) Hokkaido University Hospital / 北海道大学病院 Japan (JP) HELIOS Kliniken Germany (DE) McGill University Canada (CA) PANGAEA Oncology S.A. Spain (ES) Duke-NUS Medical School / 杜克—国大医学研究生院 Singapore (SG) Texas Oncology United States (USA) (US) Yale University United States (USA) (US) Kliniken Essen-Mitte Germany (DE) Sungkyunkwan University (SKKU) Korea, Republic of (KR) Westmead Hospital Australia (AU) Champalimaud Foundation / Fundação Champalimaud Portugal (PT) Philipps-Universität Marburg Germany (DE) Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) United States (USA) (US) University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE)

How to cite

APA:

Kuemmel, S., Fasching, P., Schmid, P., Harbeck, N., Takahashi, M., Untch, M.,... McArthur, H. (2026). ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. Annals of Surgical Oncology, 33(6), 5632-5634. https://doi.org/10.1245/s10434-026-19310-z

MLA:

Kuemmel, Sherko, et al. "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study." Annals of Surgical Oncology 33.6 (2026): 5632-5634.

BibTeX: Download